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Introduction 
Neurofibromatosis type 2 (NF2) is a rare, pre-
dominantly hereditary, genetic mutation of 
the NF2 suppressor gene on chromosome 
22. It occurs as an autosomal dominant in-
herited mutation, or as a sporadic somatic 
mutation, with up to 50% of patients present-
ing with a de novo mutation (Evans, 2009; 
Evans et al., 2019). Individuals with NF2 are 
at high risk of developing tumours of the cen-
tral nervous system; typically vestibular 
schwannomas (VS) of the eighth cranial 
nerve, but also meningiomas, ependymomas 







Introduction: We describe an Australian experience of infusional bevacizumab for vestibular 
schwannoma (VS) in neurofibromatosis type 2 patients, with specific focus on 3-dimensional tu-
mour volume and audiometry.  
 
Method: Data was pooled from patients with symptomatic or progressive VS from 2009 to April 
2018. Tumours were assessed as total volume per patient. Bevacizumab infusions were adminis-
tered every 2-4 weeks. 3-D volumetric response (cm
3
) was determined through serial magnetic res-
onance imaging, at baseline and at 3-6-month intervals, until cessation of infusions following pro-
gression or prior to surgery. Volumetric response was defined as a reduction of volume ³ 20%, from 
baseline. Patients underwent interval pure tone audiometry. A decrease in the average pure tone 
analyses by 10dB indicated response.  
 
Results: Twenty-one VS tumours were identified in eleven patients.  Median age was 26 (range 13 






).  Tumour vol-
ume reduction >20% was shown in 7/11 patients (64%), indicating partial response, 2/11 (18%) 
patients showed stable disease, and 2/11 (18%) progressed. Average percentage tumour volume 
change was +4.45% from baseline (range -57% to 241%). 16 individual ears were tested, 3/16 
(19%) of ears showed an average decibel reduction of 10dB or more, indicating response (average 
change 2.5dB, range -36dB to 81dB). 10/16 (63%) showed stable hearing, and 3/16 (19%) showed 
hearing deterioration.  
 
Conclusion: Bevacizumab is a useful agent for reducing tumour volume and improving hearing 
losses due to vestibular schwannoma in neurofibromatosis type 2 patients. These results reflect 
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The mean age of onset of symptomatic VS is 
20-30 years (Parry et al., 1994). Patients 
who develop VS tumours in childhood are 
expected to live into their thirties, and this is 
improving with modern advancements 
(Evans et al., 2019). Larger tumours incur 
worse prognosis (Otsuka, Saito, Nagatani, & 
Yoshida, 2003). Diagnosis typically follows 
investigation of hearing loss or visual disturb-
ance. VS tumours are usually bilateral, and 
associated with sensorineural hearing dys-
function, headaches, and, on occasion, cra-
nial nerve neuropathy (Bell’s palsy or trigemi-
nal disturbance), all of which can have signif-
icant impact on quality of life.  Plotkin and 
colleagues suggests an average linear 
growth rate of 1.9mm/year (Plotkin et al., 
2012; Slattery, Fisher, Iqbal, & Oppenhiemer, 
2004).  
Hearing loss is usually progressive, and has 
been traditionally managed with either surgi-
cal resection or radiation of the VS tumour 
(Halliday, Parry, & Evans, 2019; Kazim, 
Shamim, Enam, & Bari, 2011; Phi et al., 
2009; Van Gompel et al., 2018). If left unat-
tended, VS can cause increased intracranial 
pressure and even death (Evans et al., 
2000).  While the techniques on surgical re-
section and radiotherapy have been refined 
over many years, these modalities often 
leave patients with permanent deafness. 
There is a rare potential for benign tumours 
to undergo malignant transformation, thought 
to be related to previous irradiation (Evans, 
Birch, Ramsden, Sharif, & Baser, 2006). 
Therefore, while patients can achieve an ex-
tended prognosis, it is often at the expense 
of their quality of life (Otsuka et al., 2003). 
 
There have been multiple studies investigat-
ing systemic options for NF2 related VS. 
Systemic treatment is complicated by the 
elusiveness of the blood-brain barrier, and 
multiple monoclonal antibody and small mol-
ecule inhibitor agents have been proposed 
(Evans et al., 2009; Goutagny & Kala-
marides, 2018; Karajannis et al., 2012; Nigro 
et al., 2019).  
 
Bevacizumab in Neurofibromatosis Type 2  
VS tumours express vasculo-endothelial 
growth factor (VEGF) on immunohistochemi-
cal profiling (Li et al., 2016; Mautner et al., 
2010; Plotkin, Stemmer-Rachamimov, et al., 
2009). Several studies have investigated the 
effect bevacizumab, an antiangiogenic agent 
specifically targeting VEGF, to reduce the 
volume and associated hearing impairment 
related to VS tumours (Alanin et al., 2015; 
Hochart et al., 2015; Huang et al., 2018; 
Mautner et al., 2010; Morris et al., 2016; Ni-
gro et al., 2019; Plotkin, Stemmer-
Rachamimov, et al., 2009). In a cohort of ten 
patients with ten index tumours, nine tu-
mours showed treatment effect, and four pa-
tients maintained response during 11-16 
month follow up (Plotkin, Stemmer-
Rachamimov, et al., 2009). Overall, a median 
volume reduction of 26% was observed. Of 
the seven patients who were eligible for audi-
ometric analysis, four showed response, two 
had stable hearing and one deteriorated. 
This was followed up with a larger retrospec-
tive study looking at thirty-one patients, in-
cluding the ten originals (Plotkin et al., 2012). 
Again, volumetric and hearing outcomes 
were favourable; seventeen of thirty-one le-
sions had a positive volume response, and 
seventeen of twenty-three showed a positive 
audiometric response. Results were durable 
beyond one year, and more than 50% of pa-
tients had maintained their response beyond 
three years. Toxicity was typically managea-
ble. Alanin (2015) and colleagues conducted 
a 12 patient study and showed partial volu-
metric response in 50% of patients, and 11% 
response in hearing. 
 
Morris (2016) and colleagues co-ordinated a 
similar study for NF2 VS patients based in 
the UK. Data from sixty-one patients receiv-
ing bevacizumab illustrated a partial re-
sponse of tumour growth occurring in 39% of 
all tumours, and stable disease in 51%. 86% 
of patients had either a stabilisation or im-
provement of their hearing.  
 
In Australia, bevacizumab is not currently 
funded by the Pharmaceutical Benefits 
Scheme for this indication, and patients are 
currently self- funding infusions. Access pro-
grammes established throughout public hos-
pitals can assist with costs in the short term, 
however are unsustainable for ongoing infu-
sions.  
 
Audiometric Assessment  
Plotkin and colleagues have provided recom-
mendations for audiometric assessment in 
NF2 VS (Plotkin, Blakeley, et al., 2013; Plot-
kin, Halpin, et al., 2009). Pure Tone Audiom-
etry (PTA) has a sensitivity of 92% and a 
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specificity of 94% in detecting sensorineural 
hearing impairment. Audiometric volumes 
are tested from 15-30 decibels (25-30 dB for 
adults, 15-20 dB for children), and aims to 
challenge patients with tones ranging from 
500 to 4000Hz, which is reflective of the nor-
mal speech spectrum (Plotkin, Blakeley, et 
al., 2013; Plotkin, Halpin, et al., 2009). Word 
Recognition Score (WRS) assessment is the 
most accurate reflection of the speech spec-
trum, and is more widely utilised in NF2 
(Dombi et al., 2013; Plotkin, Ardern-Holmes, 
et al., 2013) 
 
Methods 
This paper is a retrospective analysis de-
scribing the effect of bevacizumab on tumour 
volume and audiometry in VS in NF2 patients 
in Australia. The primary endpoint is change 
in tumour volume and the secondary end-
point is change in audiometry.  
 
Study design and ethics 
This analysis pools data from two periods of 
treatment, looking at a total of eleven NF2 
patients. Seven patients were followed from 
2009 through to 2013, and four patients were 
followed from 2013, through to April 2018.  
This study was approved by the local Human 
Research Ethics Committee (10CHW14). 
Patients were informed of the utilisation of 
their radiological and audiometric information 
for the purposes of this study. Patient infor-
mation was de-identified and kept under 
password protected security. There was no 
interference with standard treatment proce-




All patients met clinical criteria for NF2. Pa-
tients were identified over two time periods. 
Patients from 2009 to 2013 were evaluated 
at Westmead Children’s Hospital or West-
mead Hospital. Patients were included from 
three sites in New South Wales (Prince of 
Wales Hospital, Liverpool Hospital and Royal 
Prince Alfred Hospital), Perth (Hollywood 
Private Hospital, Western Australia), Ade-
laide (Flinders Medical Centre, South Aus-
tralia), and the Gold Coast (Gold Coast Can-
cer Centre and Day Hospital, Queensland). 
Patients from 2013 to 2018 were included 
from Westmead Hospital (New South 
Wales).  
 
Patients were retrospectively analysed from 
the beginning of their treatment until Febru-
ary 2013 for the earlier cohort, and until April 
2018 for the later. Patient information includ-
ing age, gender and clinical response to 
treatment, was collected through the hospital
-centered electronic databases- (PowerChart 
and ARIA) and paper records. MRIs were 
accessed through Inteleviewer, an electronic 
image viewing portal with secure access. 
Audiometry assessments were conducted 
through local audiometry services.  
 
Assessment 
Patients were screened for factors that would 
increase risk of bevacizumab side effects; 
including uncontrolled hypertension, prior 
stroke, vascular disease (both cardiac and 
peripheral vascular), previous or current 
deep vein thrombosis, personal or family his-
tory of coagulation disorders, hepatic dys-
function or renal dysfunction, or haematolog-
ic dysfunction (MacKeith et al., 2018; Morris 
et al., 2016). No patients were pregnant or 
breast-feeding during treatment.  Advice was 
provided to patients of reproductive age to 
use contraception and avoid pregnancy dur-
ing treatment.  Fertility preservation was dis-
cussed with patients prior to commencing 
therapy.  Patients were clinically reviewed in 
between bevacizumab cycles. Blood pres-
sure and urinalysis was taken prior to every 
infusion.  A quality of life questionnaire was 
incorporated into the earlier cohort assess-
ment, however this was not conducted in the 
later cohort and as such has not been includ-
ed in this analysis. 
 
Bevacizumab infusions 
Patients received bevacizumab infusions 
through the chemotherapy suites at West-
mead Hospital, Westmead Children’s Hospi-
tal, Prince of Wales Hospital, Liverpool Hos-
pital, Royal Prince Alfred Hospital, Hollywood 
Private Hospital, Flinders Medical Centre and 
the Gold Coast Cancer Centre and Day Hos-
pital. Bevacizumab infusions were financed 
via a combination of self-funding, pharma-
ceutical special access schemes and com-
passionate access through the Hospital Drug 
Committee.  
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Dose adjustments were made based on clini-
cally assessed adverse effects, such as hy-
pertension, proteinuria, bleeding, clotting and 
general tolerability (Farschtschi, Kollmann, 
Dalchow, Stein, & Mautner, 2015; Morris et 
al., 2017; Slusarz, Merker, Muzikansky, 
Francis, & Plotkin, 2014). Infusions were 
withheld prior to any surgical procedures to 
allow for drug washout, and minimisation of 
bleeding and clotting risks, and delays in 
wound healing.  
 
Radiological measurement of response  
Magnetic Resonance Imaging (MRI) is the 
current gold standard for NF2 VS imaging 
(Dombi et al., 2013; MacKeith et al., 2018; 
Plotkin, Blakeley, et al., 2013). MRI brain 
series were collected at baseline and 3 
month intervals throughout treatment dura-
tion.  Various imaging facilities were utilised, 
based on patient preference and conven-
ience. Attempts wherever possible to com-
plete imaging at the same imaging centre 
was encouraged, for continuity of imaging 
quality. Three-dimensional (3-D) volumetric 
assessment is more sensitive and specific 
than two-dimensional (2-D) analysis and can 
detect changing volumes earlier than 2-D 
measurements. The Response Evaluation in 
Neurofibromatosis and Schwannomatosis 
(REiNS) criteria are most reliable and have 
been accepted widely as the standard criteria 
for NF2 related lesions (Dombi et al., 2013; 
Plotkin, Halpin, et al., 2009). Significant clini-
cal response is based upon a 20% change in 
3-D volumetric analysis; a 20% decrease 
indicating partial response, a 20% increase 
indicating progression, and any measures 
within these parameters considered stable 
disease. Under this criterion, surgery for the 
target lesion also constitutes radiological pro-
gression. 
 
For the earlier cohort, 3-D volumetric analy-
sis was sought from an external company, 
NFtumormetrics Group, Medical Imaging 
Centre, Massachusetts General Hospital, 
Boston; and two local radiologists at West-
mead Hospital. For the later cohort, volumet-
ric measurements were recorded from two 
separate investigators; a medical oncology 
advanced trainee, and a radiology fellow. 
Measurements were taken under guidance 
from a senior radiologist and medical oncolo-
gist at Westmead Hospital. T1 gadolinium 
contrast images were analysed, with sliced 
series ranging 1mm-5mm in the axial plane. 
VS measurements were collected inde-
pendently, and then collated for statistical 
analysis. 3-D Volumetric Analysis of tumour 
size was obtained using electronic In-
televiewer software (version 4-12-1-P115) 
Figure 1.  Scans conducted at alternative 
MRI sites could be imported to Inteleviewer, 
for standardised analysis. VS tumours were 
identified as target lesions, and other lesions 
(non-vestibular schwannoma, meningioma, 
optic nerve sheath tumours) were identified 
and measured where appropriate, though not 
included in our final analysis.  Data from both 
time periods was combined an analysed as a 
single dataset.  
 
Figure 1: Volumetric Measure of Bilateral 
VS Audiometric measurement of re-
sponse 
Patients underwent audiometric assessment, 
at baseline and then 3-6-month intervals. 
Various audiometric labs were used, based 
on patient preference and convenience.  A 
combination of PTA and WRS results were 
collected. All patients underwent PTA testing, 
however, WRS testing was not routinely con-
ducted, and thus was not included in the final 
analysis. PTA results were measured and 
analysed individually for each ear. A de-
crease in the average PTA by 10dB indicated 
response (Plotkin, Halpin, et al., 2009).  
 
Statistical analysis 
Statistical analysis was guided by a statisti-
cian. Simple descriptive statistics were calcu-
lated using Microsoft Excel Workbook, 
v16.25. NFtumormetrics volumes and local 
volumes were pooled and averaged for each 
patient for each scan. Absolute change in 
volume was expressed as a percentage for 
each patient.  
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Volume change percentage was measured 
from baseline through until last MRI on treat-
ment.  Serial PTA results were also calculat-
ed in the same manner. PTA readings were 
averaged across frequencies from 250Hz-
8000Hz and expressed in decibels (dB).  
 
Results 
Twenty-one VS tumours were identified in 
eleven patients across both time periods.  All 
patients had either clinical or radiological pro-
gression of VS tumours on commencement 
of bevacizumab infusions. The median pa-
tient age was 26 (range 13-67 years). Re-
sults are summarised in Table 1 below.  
Seven patients were identified from 2009-
2013, three females and four males. One 
patient only had a unilateral VS tumour. Five 
patients only had unilateral hearing intact at 
the time of commencement of infusions. 
Three patients also experienced symptoms 
of brainstem compression. One patient had 
significant NF2 related disability, with unilat-
eral deafness and bilateral blindness. Four 
patients had other intracranial lesions, includ-
ing meningiomas, trigeminal schwannoma 
and optic nerve sheath tumours.  
 
One patient received prior small molecule 
therapy (imatinib) before commencing 
bevacizumab. Imatinib was ineffective in this 
patient and was ceased five months prior to 
the commencement of bevacizumab therapy. 
Patients with co-morbid meningiomas, who 
were included within the first time period 
were concurrently prescribed a somatostatin 
analogue, in light of data indicating potential 
benefit for meningiomas (Chamberlain, 
Glantz, & Fadul, 2007).   
 
Four patients were analysed from 2013 to 
2018, one female and three males. All pa-
tients had bilateral VS tumours. One patient 
developed brainstem compression prior to 
commencement of bevacizumab. One pa-


















Best Hearing Response  (right/ 
left ear) 
1 22 U 27 10.79 -53 (PR R: PR, L: not tested 
2 23 B 24 5.55 -21 (PR) R: SD**, L: PD** 
3 33 B 12 16.26 -32 (PR) R: PD, L: PD 
4 22 B 9 18.51 -37 (PR) R: PR, L: SD 
5 31 B 9 38.51 -28 (PR) R: not tested, L: NA* 
6 33 B 15 3.76 -25 (PR) R: SD, L: SD 
7 13 B 9 1.77 +17 (SD) R: SD, L: not tested 
8 15 B 47 1.45 +241 (PD) R: NA*, L: NA * 
9 14 B 9 13.38 +14 (SD) R: SD, L: SD 
10 67 B 9 4.25 -57 (PR) R: SD, L: SD 
11 17 B 18 37.9 +30 (PD) R: SD then PD, L: PR then PD 
Mean: 26  17 14.17 +4.45 +2.5 (decibels) 
PR: partial response, SD: stable disease, PD: progressive disease 
* Patients had single data available, not included in analysis 
** Patient did not have baseline data, however serial data available for analysis 
not tested: no data collected (baseline deafness) 
 Table 1: Results Summary for Tumour Volume and Audiometry Response 
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neuralgia from trigeminal V3 trigeminal nerve 
compression of the VS tumour. One patient 
had a large tumour causing compression of 
the optic nerve and visual impairment of the 
right eye. This patient had complete vision 
loss in the left eye secondary to a prior left 
VS tumour.  
 
One patient had transferred from the chil-
dren’s oncology service to the adult oncology 
service. They had been treated previously 
with bevacizumab in the Children’s Hospital 
and had ceased therapy for surgical resec-
tion. This patient was restarted on bevaci-
zumab after a treatment break following sur-
gery.  
 
Most patients were commenced on a dose of 
5mg/kg given every fortnight. One patient 
(treated with concurrent imatinib) was com-
menced on 15mg/kg every 3 weeks, which 
was subsequently reduced following disease 
stabilisation, to 7.5mg/kg given every 3 
weeks. There was variability in the frequency 
of cycles, ranging from two to four weeks. 
Median duration of therapy was 9 months 
(range 9-47 months), with an average of 17 
months.  
 
Tumour Volume Response 
The average baseline total tumour volume 







).  Reduction in tumour volume of 
>20%, indicating a partial response  was 
identified in seven out of eleven patients 
(64%) (Figure 2) (Dombi et al., 2013). The 
average volume change was an increase by 
4.45%, ranging from a reduction of 57%, 
through to an increase of 241% from base-
line measurement, however this patient had 
the smallest baseline volume. Of the four 
patients who did not achieve a partial re-
sponse, two had stable disease (18%) and 
two had progression (18%) of disease.  
Figure 2: Volume Change in Unilateral VS  
At 12 months, six patients were still receiving 
infusions. The longest treatment period was 
47 months. The average length of treatment 
was 17 months.  Reasons for stopping were 
progression of disease, progression to surgi-
cal resection or cessation of funding for infu-
sions.  
 
Pure Tone Audiometry Analysis  
Results were available for 16 ears.  Two pa-
tients only had a single ear tested from base-
line. Two patients had a single result for each 
ear available, and as such were unable to be 
analysed for decibel change. One patient did 
not have a baseline data set available, how-
ever had serial PTA results available and as 
such was included in the analysis. Follow up 
for PTA analysis ranged from 6- 30 months, 
with a median of 15 months.  
 
Of the sixteen ears tested, three responded, 
19%. 10/16 ears maintained a decibel 
change between -10dB to 10dB. Three ears 
showed progression of hearing impairment.  
The average decibel change was 2.5dB, 
(range -36 to 81dB).  
 
Toxicities 
One patient was hospitalised with a viral ill-
ness and haematemesis, who also devel-
oped thrombosis around in intravenous cath-
eter. Bevacizumab was temporarily withheld, 
cautiously restarted after anticoagulation, 
with no recurrence of either bleeding or clot-
ting events. No patients were documented to 
have suffered from stroke during their 
bevacizumab treatment period. 
 
The main toxicities documented were hyper-
tension, proteinuria and fatigue, all grade 1-2 
(National Cancer, 2010). Two patients devel-
oped both hypertension and proteinuria. 
Management for these toxicities included 
antihypertensives for management of blood 
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pressure, along with a dose and frequency 
reduction in the bevacizumab dosage for ef-
fected patients. No patients ceased therapy 
due to toxicity. Fatigue was an intermittent 
symptom for most patients and likely multi-
factorial. 
 
On informal follow up, at least six patients 
ceased bevacizumab infusions due to cessa-
tion of compassionate funding, where self-
funding was not a feasible option. One pa-
tient stopped infusions to proceed with sur-
gery, another stopped to proceed with radia-
tion. At least two patients continued to self-
fund infusions.  
 
Discussion 
This study demonstrates a beneficial effect of 
bevacizumab in control of VS and hearing in 
patients with NF2. We believe this study rep-
resents the first published experience 
amongst Australian NF2 patients treated with 
bevacizumab and our results are reflective of 
those in international centres.  
 
Plotkin (2009) showed evidence of radiologi-
cal response in 6/10 (60%) of patients. Simi-
larly, Alanin (2015) studied a cohort of 12 
patients and found 6/12 (50%) of patients 
had a partial response.  
 
Plotkin (2012) again collaborated and studied 
thirty-one patients who showed 53% of pa-
tients responding in a larger cohort of thirty-
one patients, with fifty-one measurable le-
sions. Morris (2016) conducted the largest 
trial, looking at sixty-one patients, and found 
39% of their cohort showed evidence of re-
sponse.   
 
Alanin (2015)  reported a similar hearing sta-
bilisation effect of bevacizumab in a total of 9 
ears across their 12-patient cohort, and de-
scribe a response in 11%, stable hearing in 
79% and deterioration of hearing in 22%.  
We recognise that WRS analysis is a more 
sensitive measure of hearing in NF2 patients, 
however, the paucity of available WRS re-
sults within our patient cohort prevented sta-
tistical analysis. 
 
Bevacizumab toxicities were within the ex-
pected spectrum and manageable, with ap-
propriate dose and frequency modifications 
(Morris et al., 2017). There was only one ma-




The heterogeneity of volumetric assessment 
may have minor impact upon the accuracy of 
our results. Although both time periods co-
hort measurements were standardised within 
each separate time period, it would have 
been preferential to have a standardised as-
sessment process across both time periods. 
Dombi (2013) and colleagues do not specify 
whether manual measurement is preferential 
over automated measurement, but simply 
comment that measurements should be con-
sistent across the cohort and analysed cen-
trally which we upheld within the confines of 
our study. Financial restraints posed a barrier 
to accessing off site automated analysis in 
the second cohort. While measurements 
were simple to obtain on manual measure-
ment, manual techniques were time consum-
ing and would prove inefficient in larger co-
horts outside of a study environment.  
 
Future direction 
Given the durability and reproducibility of 
response rates, bevacizumab should be con-
sidered as part of the frontline management 
of VS tumours. It would offer a less invasive 
and generally more tolerable side effect pro-
file to surgery or radiotherapy, without the 
risk of malignant transformation (Evans et al., 
2006).  
 
Bevacizumab may reduce the use of steroids 
to manage VS symptoms, which in turn 
would reduce steroid related morbidity in pa-
tients who survive for extended periods with 
VS tumours and are often prescribed pro-
tracted courses of steroids and incur many 
steroid related co-morbidities.  
Li (2016) and colleagues have been investi-
gating the use of biochemical characteristics 
and changes in serial ‘dynamic contrast en-
hanced’ scans to help identify a subgroup 
within VS tumours who are more likely to 
respond to VEGF inhibition with bevaci-
zumab. This may help to further triage and 
streamline treatment modalities to offer the 
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most clinically and financially effective treat-
ment option to NF2 patients.  
 
Ideally, bevacizumab would be incorporated 
into the national funded registry (in Australia, 
the Pharmaceutical Benefits Scheme) of 
available treatment options for NF2 patients, 
thus alleviating the financial burden placed 
upon patients and their families in an attempt 
to access treatment.  
 
Conclusion 
Bevacizumab has been shown to be effective 
drug in helping to reduce tumour volume and 
improve hearing. The Australian experience 
is comparable to that illustrated in both the 
US and the UK, using standardised volumet-
ric measurement techniques and response 
criteria, and acceptable appropriation of audi-
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On 4 May, 1974, Tonnie Koenen organised 
the first meeting of Australasian neurosci-
ence nurses in Canberra, during the Neuro-
surgical Society of Australasia's annual meet-
ing.  
About 30 nurses met to formally establish the 
Australasian Neurosurgical Nurses' Associa-
tion. Since that time, Neuroscience nurses 
have continued to promote collaboration with 
other nurses and other health professionals 
in a committed effort to the professional de-
velopment and education of nurses within the 
specialty of neuroscience. We celebrate this 
and the beginning of our Association on our 
Australasian Neuroscience Nurses Day, eve-
ry 4th of May. 
The Covid-19 pandemic has shown the world 
the important role that nurses play within our 
healthcare systems.  
During this past year we have been exposed 
to enormous pressures and challenges.  
Australasian Neuroscience Nurses day is a 
day to reset and take the opportunity to 
reflect. 
We give thanks this year for the advance-
ments that have led to improvements in the 
health of so many.  
We work to support new breakthroughs in 
overcoming neurological diseases and disor-
ders.  
We hope for this pandemic to end and for no 
more lives to be lost. 
We support our colleagues as we all work to 
provide the best care that we can, always 
embracing change and innovation. 
We hope that we can have the wisdom, 
knowledge and vision to work together and 
support each other during the often long and 
lonely hours.  
Linda 
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